^
Association details:
Biomarker:NTRK2 fusion
Cancer:Solid Tumor
Drug:SIM1803-1A (ROS1 inhibitor, Trk inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Preclinical evaluation of SIM1803-1A, a small molecule Trk/ROS1 dual inhibitor for wild and mutate NTRK/ROS1 fusion solid malignancies.

Published date:
05/28/2020
Excerpt:
...studies have shown SIM1803-1A is a potent Trk/ROS1 dual inhibitor with better safety potentially from improved kinase selectivity….SIM1803-1A is currently at IND submission stage and represents a promising clinical candidate for the treatment-naïve and acquired-resistance NTRK/ROS1 fusion-positive malignancies.
DOI:
10.1200/JCO.2020.38.15_suppl.e21663